Study on the correlation between the expression of Ki67 and FasL and prognosis of cervical carcinoma

Sn, Liang; Yj, Huang; Liu, L-L; Liu, Xiaoyu

doi:10.4238/2015.july.31.11

Cited by 8 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, the combination of FA-chitosan/mIP-10 and FC vaccine significantly reduced the number of Ki67 + tumor cells but increased the number of apoptotic cells in the tumor tissues which was consistent with the previous reports 31, 32, 33. These data suggest that Th1 and CTL cells induced by combination therapy inhibit the proliferation of tumor cells and trigger apoptosis by direct cell-cell contact or indirectly by soluble mediators.…”

Section: Discussionsupporting

confidence: 93%

Mouse IP-10 Gene Delivered by Folate-modified Chitosan Nanoparticles and Dendritic/tumor Cells Fusion Vaccine Effectively Inhibit the Growth of Hepatocellular Carcinoma in Mice

Hu¹,

Chen²,

Zhou³

et al. 2017

Theranostics

View full text Add to dashboard Cite

Dendritic cells (DC) and tumor cell fusion vaccine (DC/tumor cell fusion vaccine) is considered an effective approach in cancer biotherapy. However, its therapeutic effects in early clinical trials have been suboptimal partially due to the immunosuppressive tumor environment. In this study, we used nanoparticles of folate (FA)-modified chitosan, a non-viral vector capable of targeting tumor cells with high expression of FA receptors. FA-chitosan nanoparticles were used as biological carriers for the expression plasmid of the mouse interferon-induced protein-10 (mIP-10) gene, a potent chemoattractant for cytotoxic T cells. The combination of FA-chitosan/mIP-10 and DC/tumor cell fusion vaccine against hepatocellular carcinoma (HCC) effectively inhibited the growth of implanted HCC tumors and prolonged the survival of mice. The combination therapy significantly reduced myeloid-derived suppressor cells (MDSC) in mouse spleen, local tumor, and bone marrow while increasing tumor-specific IFN-γ responses. Furthermore, the combination therapy significantly inhibited tumor cell proliferation while promoting their apoptosis. Taken together, our data illustrate that the mIP-10 enhances the anti-tumor effect of DC/tumor cell fusion vaccine by alleviating the immunosuppressive tumor environment.

show abstract

Section: Discussionsupporting

confidence: 93%

Mouse IP-10 Gene Delivered by Folate-modified Chitosan Nanoparticles and Dendritic/tumor Cells Fusion Vaccine Effectively Inhibit the Growth of Hepatocellular Carcinoma in Mice

Hu¹,

Chen²,

Zhou³

et al. 2017

Theranostics

View full text Add to dashboard Cite

show abstract

“…12,13 According to previous studies, high KI67 expression in CC is related to the size of tumors, progression of tumors, and lymph node metastases. 14 Gene set enrichment analysis (GSEA) analysis showed that biological pathways, such as cell cycle, oocyte meiosis, RNA degradation, and fatty acid metabolism and biosynthesis were enriched in cluster 3 (Figure 2E). Meanwhile, cluster 3 was found to have higher levels of G 2 /M signatures, suggesting high proliferative activity.…”

Section: Single-cell Transcriptomics Reveal Intra-tumoral Heterogeneity In CC Cellsmentioning

confidence: 99%

Single-cell transcriptomics reveals the landscape of intra-tumoral heterogeneity and transcriptional activities of ECs in CC

Guo

et al. 2021

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

Cervical cancer (CC) is the fourth leading cause of deaths in gynecological malignancies. Although the etiology of CC has been extensively investigated, the exact pathogenesis of CC remains incomplete. Recently, single-cell technologies demonstrated advantages in exploring intra-tumoral diversification among various tumor cells. However, single-cell transcriptome analysis (single-cell RNA sequencing [scRNA-seq]) of CC cells and microenvironment has not been conducted. In this study, a total of 20,938 cells from CC and adjacent normal tissues were examined by scRNA-seq. We identified four tumor cell subpopulations in tumor cells, which had specific signature genes with different biological functions and presented different prognoses. Among them, we identified a subset of cancer stem cells (CSCs) that was related to the developmental hierarchy of tumor progression. Then, we compared the expressive differences between tumor-derived endothelial cells (TECs) and normal ECs (NECs) and revealed higher expression of several metabolism-related genes in TECs. Then, we explored the potential biological function of ECs in vascularization and found several marker genes, which played a prior role in connections between cancer cells and ECs. Our findings provide valuable resources for deciphering the intra-tumoral heterogeneity of CC and uncover the developmental procedure of ECs, which paves the way for CC therapy.

show abstract

“…Ki67 is a nuclear protein, and its expression level is strongly associated with tumor cell proliferation and growth and is widely used in routine pathological investigations as a proliferation marker. Clinically, Ki67 expression is significantly higher in malignant tissues with poorly differentiated tumor cells than in normal tissue [21,22]. In cervical cancer, the expression of Ki67 is closely related to the occurrence and development of cervical carcinoma [22].…”

Section: Patientmentioning

confidence: 99%

“…Clinically, Ki67 expression is significantly higher in malignant tissues with poorly differentiated tumor cells than in normal tissue [21,22]. In cervical cancer, the expression of Ki67 is closely related to the occurrence and development of cervical carcinoma [22]. Therefore, the expression of SCCA and Ki67 levels were evaluated in our study for prognostic research.…”

Section: Patientmentioning

confidence: 99%

Radiomics model of 18F-FDG PET/CT imaging for predicting disease-free survival of early-stage uterine cervical squamous cancer

Liu

et al. 2022

CBM

View full text Add to dashboard Cite

BACKGROUND: To explore an effective predictive model based on PET/CT radiomics for the prognosis of early-stage uterine cervical squamous cancer. METHODS: Preoperative PET/CT data were collected from 201 uterine cervical squamous cancer patients with stage IB-IIA disease (FIGO 2009) who underwent radical surgery between 2010 and 2015. The tumor regions were manually segmented, and 1318 radiomic features were extracted. First, model-based univariate analysis was performed to exclude features with small correlations. Then, the redundant features were further removed by feature collinearity. Finally, the random survival forest (RSF) was used to assess feature importance for multivariate analysis. The prognostic models were established based on RSF, and their predictive performances were measured by the C-index and the time-dependent cumulative/dynamics AUC (C/D AUC). RESULTS: In total, 6 radiomic features (5 for CT and 1 for PET) and 6 clinicopathologic features were selected. The radiomic, clinicopathologic and combination prognostic models yielded C-indexes of 0.9338, 0.9019 and 0.9527, and the mean values of the C/D AUC (mC/D AUC) were 0.9146, 0.8645 and 0.9199, respectively. CONCLUSIONS: PET/CT radiomics could achieve approval power in predicting DFS in early-stage uterine cervical squamous cancer.

show abstract

Study on the correlation between the expression of Ki67 and FasL and prognosis of cervical carcinoma

Cited by 8 publications

References 13 publications

Mouse IP-10 Gene Delivered by Folate-modified Chitosan Nanoparticles and Dendritic/tumor Cells Fusion Vaccine Effectively Inhibit the Growth of Hepatocellular Carcinoma in Mice

Mouse IP-10 Gene Delivered by Folate-modified Chitosan Nanoparticles and Dendritic/tumor Cells Fusion Vaccine Effectively Inhibit the Growth of Hepatocellular Carcinoma in Mice

Single-cell transcriptomics reveals the landscape of intra-tumoral heterogeneity and transcriptional activities of ECs in CC

Radiomics model of 18F-FDG PET/CT imaging for predicting disease-free survival of early-stage uterine cervical squamous cancer

Contact Info

Product

Resources

About